OUTSTANDING INVESTIGATOR

发现结构新颖且可能非常重要的抗癌药物 来自动物、植物和微生物的物质将继续形成 更新杰出研究员奖助金的明确目标 (OIG)国家癌症研究所(NCI)的研究。以提供 目前优秀的最终临床试验的最佳候选者 我们在中国发现的海洋动植物抗癌物质 与海绵他汀类、Dolastatins、Halistatins和 头孢他汀类药物，将更多地强调获得新成员 并在进一步研究的同时阐明它们的结构 扩大Bryostatin临床试验所需的研究知识 1.积极的平行研究将继续有力地集中在 新化合物的分离、表征及结构测定 可能有用的抗癌药物来自海洋动物、植物和 微生物。OIG程序将用于分离和表征 从确认的海洋活性提取物中提取的抗癌新药 无脊椎动物和脊椎动物，海洋和陆地植物，以及海洋 微生物。重点将放在海洋动植物上。 产生具有突出确认活性的提取物的物种 在NCI的人类癌细胞系统中，小鼠异种移植和哪里 适当的、新的微生物和生化类型预选方法。 只有那些给出最大希望生产新药的物种 潜在的临床活动将利用OIG资金进行。其他类似的 优先程度较低的线索将通过任何其他财政支持进行追查 这可能是可用的。因为36年来一直致力于 为这项抗癌药物发现研究奠定了基础 大量极具前景的动物、微生物和植物 物种已经被发现，并将与新的 已开发的领导保持非常有生产力的潜在有用的产出 具有独特结构的抗肿瘤物质。一如既往的更新 OIG计划将极大地帮助DCT-NCI选择新的抗癌药物 候选药物，加快其向临床试验的发展。在……里面 总结说，整体更新OIG计划将重点放在 抗癌新药的发现和快速发展 国家癌症研究所旨在改善人类癌症的计划 治疗。

Discovery of structurally novel and potentially very important cancer drugs from animal, plant and microorganism sources will continue to form the sharply focused objective of the renewal Outstanding Investigator Grant (OIG) research for the National Cancer Institute (NCI). To provide the best candidates for eventual clinical trial among the current outstanding marine animal and plant anticancer substances we have discovered in collaboration with the spongistatins, dolastatins, halistatins and cephalostatins, additional emphasis will be placed on obtaining new members of these series and elucidating their structures while further advancing research knowledge necessary to the expanding clinical trials of bryostatin 1. Vigorous parallel research will continue to be strongly focused on the isolation, characterization and structural determination of new and potentially useful anticancer drugs from marine animals, plants and microorganisms. The OIG program would be used to isolate and characterize such new anticancer drugs from confirmed active extracts of marine invertebrates and vertebrates, marine and terrestrial plants, and marine microorganisms. The principal focus would be upon marine animal and plant species yielding extracts with an outstanding level of confirmed activity in the NCI's human cancer cell systems, murine xenografts and where appropriate, new microorganism and biochemical type preselection methods. Only those species that give maximum promise of yielding new drugs with potential clinical activity will be pursued with OIG funds. Other such leads of a lesser priority will be pursued with any other financial support that might be available. Because of 36 years devoted exclusively to constructing the foundation for this anticancer drug discovery research, a good number of exceedingly promising animal, microorganism and plant species have already been uncovered and will be used along with newly developed leads to maintain a very productive output of potentially useful antineoplastic substances of unique structure. As in the past the renewal OIG program will greatly assist the DCT-NCI in selecting new anticancer drug candidates and speeding their development toward clinical trial. In summary, the overall renewal OIG program will be sharply focused on the discovery and very rapid development of new anticancer drugs for the National Cancer Institute's programs directed at improving human cancer treatments.